Dexcom Data Engineer Salary by Level

The 6 data engineer offers behind the ladder split between 2 sources: verified self-reported offers where total comp, base, and equity are confirmed directly, and public filings that capture base salary only, with bonus and equity estimated from peer ratios in the Healthcare sector. All 6 reports land at the same seniority band, L4, so the $180K median reflects a single career stage with no cross-level averaging to dilute it. That concentration makes the figure more reliable than a blended number, but a sample this thin means 1 outlier report shifts the median visibly. Reports from the past 18 months carry the most weight; older offers from this company are modeled with a steeper discount given how quickly GCP-native roles have repriced. Treat the range more seriously than the point estimate here: with 6 offers the range captures real spread, and an offer outside $171K-$198K is worth investigating before accepting it as typical.

Dexcom structures data engineer comp as a base-plus-equity arrangement typical of mid-size medical device companies, without the aggressive equity refresh cycles that pure software or consumer-tech firms run. Base accounts for the majority of annual realized pay, and RSU grants vest over a 4-year schedule with a front-weighted cliff; the headline total comp figure folds in the annualized grant value at the grant price, so what you actually realize depends on DXCM's stock performance over the vest window. Bonus targets at this level are modest relative to the equity component, and Dexcom's margin profile as a hardware-plus-software regulated device company doesn't support the outsized cash bonuses that cloud or fintech platforms offer. The practical implication: the gap between offered total comp and realized first-year pay can be real, especially if RSUs are granted at a price above current trading levels when you join.

Dexcom pay landing above other Healthcare companies is a meaningful spread given that Healthcare as a sector generally pays data engineers below the broader tech market. The likeliest driver is a talent-market dynamic: Dexcom competes for engineers who can work in HIPAA-regulated environments with clinical data obligations, a narrower pool than general-purpose data engineering. Companies in that position tend to close the gap with base rather than equity, because device-company stock is less compelling than hyperscaler equity as a recruitment tool. A secondary factor, consistent with the GCP-and-Iceberg stack, is that Dexcom has invested in cloud infrastructure that attracts engineers with warehouse and lakehouse experience, and those profiles command a premium right now regardless of industry. The above-market position also reads as partly structural: San Diego is not a saturated tech labor market, so Dexcom can pay above regional Healthcare peers without matching Bay Area or Seattle levels.

With 1 band in the data, there's no title jump available to change the outcome: you're negotiating within a single rung, which means the room lives in components rather than titles. Base is the component most likely to flex. The range at L4 spans $171K-$198K, a spread wide enough that your opening number matters: most offers land in the lower half of that band and move on a competing offer or a documented market reference, not on role-scope arguments. RSU grant size is a second component worth pushing on, though Dexcom's refresh history is thinner than what you'd find at a software-first company, so treat the initial grant as the primary equity event. Bonus targets are largely fixed by band. The single highest-value move before finalizing an offer is pulling a competing Healthcare-sector DE offer at a company running a similar regulated-data stack; that comparison gives you concrete ground to push base toward the top of the range rather than negotiating against a number Dexcom already knows you'll accept.